{"result": {"id": "dac80abc-c3aa-4a59-b7c9-c57af0f53941", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CARES<|>EVENT<|>CARES is a study comparing the cardiovascular safety of febuxostat and allopurinol in gout patients with cardiovascular diseases)\n##\n(\"entity\"<|>非布司他<|>PERSON<|>Febuxostat is a medication used to treat gout, but it may increase the risk of death in patients with cardiovascular diseases)\n##\n(\"entity\"<|>别嘌醇<|>PERSON<|>Allopurinol is a medication used to treat gout and was compared to febuxostat in the CARES study)\n##\n(\"entity\"<|>苯溴马隆<|>PERSON<|>Benzbromarone is a medication used to treat gout, with specific dosing recommendations based on kidney function)\n##\n(\"entity\"<|>拉布立酶<|>PERSON<|>Rasburicase is an enzyme used to treat refractory gout or significant acute hyperuricemia, but it is not available in China)\n##\n(\"entity\"<|>普瑞凯希<|>PERSON<|>Pegloticase is an enzyme used to treat refractory gout or significant acute hyperuricemia, but it is not available in China)\n##\n(\"entity\"<|>RDEA594<|>PERSON<|>Lesinurad is a novel urate-lowering drug that inhibits renal tubular urate transporter 1 and organic acid transporter, not yet available in China)\n##\n(\"entity\"<|>中华内科杂志<|>ORGANIZATION<|>Chinese Journal of Internal Medicine is a medical journal publishing the guidelines and studies mentioned in the text)\n##\n(\"relationship\"<|>非布司他<|>CARES<|>Febuxostat was studied in the CARES research for its cardiovascular safety<|>8)\n##\n(\"relationship\"<|>别嘌醇<|>CARES<|>Allopurinol was compared to febuxostat in the CARES research<|>8)\n##\n(\"relationship\"<|>非布司他<|>别嘌醇<|>Febuxostat and allopurinol were compared in the CARES study for their cardiovascular safety in gout patients<|>7)\n##\n(\"relationship\"<|>拉布立酶<|>普瑞凯希<|>Both rasburicase and pegloticase are enzymes used for refractory gout but are not available in China<|>6)\n##\n(\"relationship\"<|>RDEA594<|>中华内科杂志<|>Lesinurad (RDEA594) is mentioned in the Chinese Journal of Internal Medicine as a novel urate-lowering drug<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751559116, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 580, "prompt_tokens": 2456, "total_tokens": 3036, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 664}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ml/min）者 无 须 调 整 剂 量 ，重 度 肾 功 能 不 全 （eGFR<30 ml/min）者慎用 。基于非布司他和别嘌 醇用于合并心血管疾病痛风患者中的心血管安全 性（CARES）研究，非布司他可增加合并心血管疾病 的痛风患者的死亡风险，虽然目前尚无定论，但对 有心血管疾病病史或新发心血管疾病者，需谨慎使 用并随访监测，警惕心血管事件的发生。\n（3）苯溴马隆：成人起始剂量 25~50 mg/d，每\n4 周左右监测血尿酸水平，若不达标，则缓慢递增 剂量至 75~ 100 mg/d 。可用于轻中度肾功能异常或 肾移植患者，eGFR 为 20~60 ml/min 者推荐剂量不 超过 50 mg/d；eGFR<20 ml/min 或尿酸性肾石症患 者禁用 。对使用促尿酸排泄药物是否需要碱化尿 液仍有争议，2020 年美国风湿病学会痛风管理指 南不建议碱化尿液治疗 。 国内专家建议视个体情 况而定，若患者合并尿酸性肾结石，和/或尿 pH 值 小于 5，依然建议给予适当碱化尿液治疗，并且需 要监测尿 pH 值。\n　　（4）其他降尿酸药物：对难治性痛风、其他药物 疗效不佳或存在禁忌证、血液系统恶性肿瘤或放化 疗所致的急性血尿酸显著升高，可考虑使用尿酸\n\n\n\n中华内科杂志 2023 年 9 月第 62 卷第 9 期    Chin J Intern Med, September 2023, Vol. 62, No. 9                                                                      ·  1073    ·\n\n\n　酶 ，包 括 拉 布 立 酶（rasburicase）和 普 瑞 凯 希  （pegloticase），目前国内均未上市，不建议将其作为  一线用药 。新型降尿酸药物 RDEA594（lesinurad）， 通过抑制肾小管尿酸转运蛋白?1 和有机酸转运子  发挥作用，用于单一足量使用黄嘌呤氧化酶抑制剂  治疗仍不能达标的痛风患者，可与黄嘌呤氧化酶抑  制剂联合使用 。 目前该药尚未在国内上市。\n（三）急性期治疗\n　　　急性期治疗原则是快速控制关节炎症和疼痛。 急性期应卧床休息，抬高患肢，最好在发作 24 h 内  开始应用控制急性炎症的药物 。一线治疗药物有  秋水仙碱和非甾体抗炎药，当存在治疗禁忌或治疗  效果不佳时，亦可考虑短期应用糖皮质激素抗炎治  疗 。若单药治疗效果不佳，可选择上述药物联合治  疗 。对上述药物不耐受或有禁忌时，国外亦有使用  白细胞介素（IL）?1 受体拮抗剂作为二线痛风急性  发\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_85f6ba3ae3caeb1077365094a0400dd942a214d944746a8377dbee9af37d0a69_v2"}